ERBB2 and breast cancer: Thompson et al. [91] published original data regarding Paraoxonase-1 (PON-1) activity in a breast cancer population (N = 184) treated with doxorubicin ± trastuzumab (17.8% received), including both HER2-negative and -positive patients.